49549-75-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(1H-Imidazol-4-yl)-1-propanol is used as a building block for the synthesis of antifungal and antimicrobial agents due to its unique chemical structure that can be incorporated into various medicinal compounds to enhance their therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(1H-Imidazol-4-yl)-1-propanol serves as an intermediate in the development of compounds designed to protect crops from pests and diseases, leveraging its reactivity and structural features to create effective agrochemical products.
Used in Specialty Chemicals Production:
3-(1H-Imidazol-4-yl)-1-propanol is utilized in the production of surfactants and other specialty chemicals, where its chemical properties allow for the creation of compounds with specific characteristics required in various industrial applications.
Overall, 3-(1H-Imidazol-4-yl)-1-propanol is a multifaceted chemical with a diverse array of applications across different industries, underscoring its importance in modern chemical synthesis and product development.

Upstream product

• 52237-38-4 ethyl 3-(imidazol-4'-yl)-propanoate 
• 5324-21-0 3-bromo-2-methoxy-tetrahydropyran 
• 77287-34-4 formamide 
• 31434-93-2 methyl 3-(4-imidazolyl)propionate 
• 7732-18-5 water 
• 3473-63-0 formamidine acetic acid 
• 70346-51-9 (E)-methyl 3-(1H-imidazol-4-yl)acrylate 
• 3465-72-3 urocanic Acid 
• 1074-59-5 3-(imidazol-4-yl)propionic acid 
• 110-87-2 3,4-dihydro-2H-pyran 
• 104-98-3 urocanic acid 

Downstream Products

• 152030-49-4 3-(1-trityl-1H-imidazol-4-yl)propan-1-ol 
• 102676-90-4 5-(3-chloropropyl)-1-<(4-cyanophenyl)methyl>-1H-imidazole hydrochloride 
• 102676-29-9 1-<(4-cyanophenyl)methyl>-1H-imidazole-5-propanol 
• 152030-52-9 1-triphenylmethyl-4-[3-(4-trifluoromethylphenoxy)propyl]-1H-imidazole 
• 152030-50-7 4-[3-(1-Trityl-1H-imidazol-4-yl)-propoxy]-benzonitrile 
• 1027314-06-2 1-triphenylmethyl-4-[3-(4-fluorophenoxy)propyl]-1H-imidazole 
• 152030-48-3 UCL 1390 
• 214898-10-9 4-[3-(4-trimethylsilanylethynyl-phenoxy)-propyl]-imidazole-1-carboxylic acid tert-butyl ester 
• 214898-08-5 4-[3-(4-pent-1-ynyl-phenoxy)-propyl]-imidazole-1-carboxylic acid tert-butyl ester 
• 214898-09-6 4-{3-[4-(3,3-dimethyl-but-1-ynyl)-phenoxy]-propyl}-imidazole-1-carboxylic acid tert-butyl ester 
• 214898-07-4 4-[3-(4-prop-1-ynyl-phenoxy)-propyl]-imidazole-1-carboxylic acid tert-butyl ester 
• 183155-63-7 3-(1-triphenylmethyl-1H-imidazol-4-yl)propyl 4-fluorobenzyl ether 
• 209599-09-7 4-but-3-ynyl-1-(triphenylmethyl)imidazole 
• 102676-61-9 3-(1-triphenylmethyl-4-imidazolyl)propionaldehyde 

Relevant academic research and scientific papers

Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease

A series of novel propargylamine-modified pyrimidinylthiourea derivatives (1–3) were designed and synthesized as multifunctional agents for Alzheimer's disease (AD) therapy, and their potential was evaluated through various biological experiments. Among these derivatives, compound 1b displayed good selective inhibitory activity against AChE (vs BuChE, IC50 = 0.324 μM, SI > 123) and MAO-B (vs MAO-A, IC50 = 1.427 μM, SI > 35). Molecular docking study showed that the pyrimidinylthiourea moiety of 1b could bind to the catalytic active site (CAS) of AChE, and the propargylamine moiety interacted directly with the flavin adenine dinucleotide (FAD) of MAO-B. Moreover, 1b demonstrated mild antioxidant ability, good copper chelating property, effective inhibitory activity against Cu2+-induced Aβ1?42 aggregation, moderate neuroprotection, low cytotoxicity, and appropriate blood?brain barrier (BBB) permeability in vitro and was capable of ameliorating scopolamine-induced cognitive impairment in mice. These results indicated that 1b has the potential to be a multifunctional candidate for the treatment of Alzheimer's disease.

Triazole ligands reveal distinct molecular features that induce histaine H4 receptor affinity and subtly govern H4/H3 subtype selectivity

The histamine H3 (H3R) and H4 (H 4R) receptors attract considerable interest from the medicinal chemistry community. Given their relatively high homology yet widely differing therapeutic promises, ligand selectivity for the two receptors is crucial. We interrogated H4R/H3R selectivities using ligands with a [1,2,3]triazole core. Cu(I)-assisted "click chemistry" was used to assemble diverse [1,2,3]triazole compounds (6a-w and 7a-f), many containing a peripheral imidazole group. The imidazole ring posed some problems in the click chemistry putatively due to Cu(II) coordination, but Boc protection of the imidazole and removal of oxygen from the reaction mixture provided effective strategies. Pharmacological studies revealed two monosubstituted imidazoles (6h,p) with 4R affinities and >10-fold H 4R/H3R selectivity. Both compounds possess a cycloalkylmethyl group and appear to target a lipophilic pocket in H 4R with high steric precision. The use of the [1,2,3]triazole scaffold is further demonstrated by the notion that simple changes in spacer length or peripheral groups can reverse the selectivity toward H3R. Computational evidence is provided to account for two key selectivity switches and to pinpoint a lipophilic pocket as an important handle for H4R over H3R selectivity.

Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: Synthesis, pharmacological evaluation, and cross-target QSAR studies

Previous studies have demonstrated that clobenpropit (N-(4-chlorobenzyl)-S-[3-(4(5)-imidazolyl)propyl]isothiourea) binds to both the human histamine H3 receptor (H3R) and H4 receptor (H4R). In this paper, we describe the synthesis and pharmacological characterization of a series of clobenpropit analogs, which vary in the functional group adjacent to the isothiourea moiety in order to study structural requirements for H3R and H4R ligands. The compounds show moderate to high affinity for both the human H3R and H4R. Furthermore, the changes in the functional group attached to the isothiourea moiety modulate the intrinsic activity of the ligands at the H4R, ranging from neutral antagonism to full agonism. QSAR models have been generated in order to explain the H3R and H4R affinities.

2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION

The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) , or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION

A 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented by the generalformula (1): [Chemical formula 1] (1) or a pharmaceutically acceptable saltthereof. They are useful as a therapeutic/preventive agent for diabetes, diabeticnephropathy, or glomerulosclerosis.

Hydantoin derivatives as non-peptidic inhibitors of Ras farnesyl transferase

1,3,5,5-Tetrasubstituted 2,4-imidazolinedione (hydantoin) derivatives were evaluated as Ftase inhibitors. Potent Ftase inhibitors without thiol or peptide were obtained in three steps.

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Synthesis of 3-[1H-imidazol-4-yl] propyl 4-[18F] fluorobenzyl ether ([18F] fluoroproxyfan): A potential radioligand for imaging histamine H3 receptors

3-[1H-Imidazol-4-yl]propyl 4-fluorobenzyl ether (fluoroproxyfan), a potential histamine H3 receptor ligand, was labeled with 18F for clinical PET studies. The synthesis involved the O-alkylation of 3-(1 -triphenylmethyl-1H-imidazol-4

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras

A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists

[[(4-Nitrophenyl)X]alkyl]imidazole isosteres (where X = NH, S, CH2S, O) of previously described [[(5-nitropyrid-2-yl)X]ethyl]imidazoles (where X = NH, S) have been synthesized and evaluated for H3-receptor histamine antagonism in vitro (K(i) for [3H]histamine release from rat cerebral cortex synaptosomes) and in vivo (ED50 per os in mice on brain tele- methylhistamine levels). Encouraging results led to the synthesis and testing of a novel series of substituted (phenoxyethyl)- and (phenoxypropyl)imidazoles. From the latter, 4-[3-(4-cyanophenoxy)propyl]-1H- imidazole (10a, UCL 1390; K(i) = 12 nM, ED50 = 0.54 mg/kg) and 4-[3-[4- (trifluoromethyl)-phenoxy]propyl]-1H-imidazole (10c, UCL 1409; K(i) = 14 nM, ED50 = 0.60 mg/kg) have been selected as potential candidates for drug development. For 16 [(aryloxy)ethyl]imidazoles the relationship between in vitro and in vivo potency is described by the equation log ED50 = 0.47 log K(i) + 0.20 (r = 0.78).